Immunogen’s (NASDAQ:IMGN) Expectations Too High, as is Valuation
Immunogen’s (NASDAQ:IMGN) valuation is too high, according to Needham, which is the result of expectations concerning late-stage T-DM1. Needham says, “We believe the current valuation is built on high expectations for the late-stage T-DM1 along with the brand-name Roche (OTC:RHHBY) (N/R) partnership, but the value creation for ImmunoGen is modest, due to the mid-single digit royalty. Despite the
Read the original here:
Immunogen’s (NASDAQ:IMGN) Expectations Too High, as is Valuation
Tags: built-on-high, economy, immuno, roche, the-mid-single, the-result, too-high, value-creation
